Back

Modulation of all-trans retinoic acid by light and dopamine in the murine eye

Talwar, S.; Mazade, R.; Bentley-Ford, M.; Yu, J.; Pilli, N.; Kane, M. A.; Ethier, C. R.; Pardue, M. T.

2024-12-12 systems biology
10.1101/2024.12.06.627245 bioRxiv
Show abstract

PurposeAmbient light exposure is linked to myopia development in children and affects myopia susceptibility in animal models. Currently, it is unclear which signals mediate the effects of light on myopia. All-trans retinoic acid (atRA) and dopamine (DA) oppositely influence experimental myopia and may be involved in the retino-scleral signaling cascade underlying myopic eye growth. However, how ocular atRA responds to different lighting and whether atRA and DA interact remains unknown. MethodsDark-adapted C57BL/6J mice (29-31 days old) were exposed to Dim (1 lux), Mid (59 lux), or Bright (12,000 lux) ambient lighting for 5-60 minutes. Some mice were also systemically administered the DA precursor, LDOPA, or atRA prior to light exposure. After exposure, the retina and the back-of-the-eye (BOE) were collected and analyzed for levels of atRA, DA, and the DA metabolite, DOPAC. ResultsDA turnover (DOPAC/DA ratio) in the retina increased in magnitude after only five minutes of exposure to higher ambient luminance but was minimal in the BOE. In contrast, atRA levels in the retina and BOE significantly decreased with higher ambient luminance and longer duration exposure. Intriguingly, LDOPA-treated mice had a transient reduction in retinal atRA compared to saline-treated mice, whereas atRA treatment had no effect on ocular DA. ConclusionsOcular atRA was affected by the duration of exposure to different ambient lighting and retinal atRA levels decreased with increased DA. Overall, these data suggest specific interactions between ambient lighting, atRA, and DA that could have implications for the retino-scleral signaling cascade underlying myopic eye growth.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 10%
17.9%
2
FASEB BioAdvances
15 papers in training set
Top 0.1%
9.3%
3
Scientific Reports
3102 papers in training set
Top 9%
8.6%
4
Frontiers in Medicine
113 papers in training set
Top 0.4%
7.3%
5
Investigative Opthalmology & Visual Science
37 papers in training set
Top 0.2%
3.7%
6
Biomolecules
95 papers in training set
Top 0.1%
2.9%
7
Experimental Eye Research
30 papers in training set
Top 0.3%
2.1%
50% of probability mass above
8
Frontiers in Physiology
93 papers in training set
Top 2%
2.1%
9
The FASEB Journal
175 papers in training set
Top 0.7%
1.9%
10
Pigment Cell & Melanoma Research
11 papers in training set
Top 0.1%
1.7%
11
Biophysical Journal
545 papers in training set
Top 3%
1.7%
12
Frontiers in Endocrinology
53 papers in training set
Top 1%
1.7%
13
Experimental Dermatology
10 papers in training set
Top 0.1%
1.7%
14
Frontiers in Aging Neuroscience
67 papers in training set
Top 2%
1.7%
15
Translational Vision Science & Technology
35 papers in training set
Top 0.4%
1.7%
16
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 5%
1.5%
17
Frontiers in Neuroscience
223 papers in training set
Top 5%
1.4%
18
iScience
1063 papers in training set
Top 19%
1.4%
19
eLife
5422 papers in training set
Top 48%
1.3%
20
The Journal of Nutrition
21 papers in training set
Top 0.5%
0.9%
21
Brain Research
35 papers in training set
Top 1%
0.9%
22
Gigabyte
60 papers in training set
Top 1%
0.8%
23
Frontiers in Molecular Biosciences
100 papers in training set
Top 4%
0.8%
24
Journal of Biological Chemistry
641 papers in training set
Top 4%
0.8%
25
PLOS Global Public Health
293 papers in training set
Top 5%
0.8%
26
Ophthalmology Science
20 papers in training set
Top 0.2%
0.8%
27
Journal of Clinical Medicine
91 papers in training set
Top 6%
0.8%
28
Frontiers in Neurology
91 papers in training set
Top 5%
0.7%
29
Journal of Experimental Zoology Part B: Molecular and Developmental Evolution
22 papers in training set
Top 0.7%
0.7%
30
Frontiers in Nutrition
23 papers in training set
Top 2%
0.7%